Physician profile
Robert Greig Trapp
NPI 1841363751
$8,709.35
in general payments reported to CMS, 2019-2025
22 companies · $710 in 2025
The $710 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,074 · 2020: $662 · 2021: $1,241 · 2022: $1,593 · 2023: $1,698 · 2024: $1,731 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,042 · Education: $98.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,041.82 |
| Education | $98.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,670.19 | 2019-2025 | Enbrel, Otezla, Otezla |
| Abbvie INC. | $1,827.36 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $994.50 | 2019-2025 | |
| Ucb, INC. | $836.48 | 2021-2025 | Cimzia, Bimzelx |
| Horizon Therapeutics Plc | $511.08 | 2020-2023 | Krystexxa |
| Lilly USA, LLC | $418.74 | 2019-2023 | Taltz |
| Janssen Biotech, INC. | $256.18 | 2021-2025 | Tremfya |
| Celgene Corporation | $233.31 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $205.48 | 2022-2025 | Saphnelo |
| Genentech USA, INC. | $184.49 | 2019-2020 | |
| Pfizer INC. | $146.40 | 2020-2025 | |
| Janssen Scientific Affairs, LLC | $114.39 | 2021 | |
| Bioventus LLC | $88.72 | 2019-2021 | |
| Sandoz INC. | $53.89 | 2023-2024 | Hyrimoz |
| E.R. Squibb & Sons, L.L.C. | $46.62 | 2021-2024 | Orencia |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $40.43 | 2023-2024 | Idacio |
| Genzyme Corporation | $38.21 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.56 | 2024 | Cyltezo |
| Pacira Therapeutics, INC. | $17.32 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Trapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.